Results 11 to 20 of about 26,462 (230)

P2Y12 receptor gene polymorphisms are associated with epilepsy. [PDF]

Purinergic Signal, 2023
AbstractThe basic research indicated that microglial P2Y12 receptors (P2Y12Rs) are involved in the pathophysiology of epilepsy through regulated microglial-neuronal interactions, aberrant neurogenesis, or immature neuronal projections. However, whether the clinic case of epilepsy would be associated with P2Y12 receptor gene polymorphisms is presented ...
Wang Q, Shi NR, Lv P, Liu J, Zhang JZ, Deng BL, Zuo YQ, Yang J, Wang X, Chen X, Hu XM, Liu TT, Liu J.   +12 more
europepmc   +4 more sources

P2Y12 receptor blockers are anti-inflammatory drugs inhibiting both circulating monocytes and macrophages including THP-1 cells

Scientific Reports, 2021
P2Y12 blockade improves patient outcomes after myocardial infarction. As well as antithrombotic effects, anti-inflammatory effects may contribute to this beneficial clinical outcome.
Patrick M. Siegel, Laura Sander, Alba Fricke, Johannes Stamm, Xiaowei Wang, Prerna Sharma, Nicole Bassler, Ya-Lan Ying, Christoph B. Olivier, Steffen U. Eisenhardt, Christoph Bode, Ingo Ahrens, Philipp Diehl, Karlheinz Peter   +13 more
doaj   +1 more source

The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration

Platelets, 2022
Here, we report the in vitro characterization of the P2Y12 receptor antagonist selatogrel (ACT-246475). Binding studies with radiolabeled selatogrel demonstrated that selatogrel is a competitive antagonist of ADP binding to the P2Y12 receptor with a fast
Martine Baumann, Benoît Lack, Isabelle Guillaumat, Mark J. Murphy, Markus A. Riederer   +4 more
doaj   +1 more source

P2Y12 Antagonists in Cardiovascular Disease—Finding the Best Balance Between Preventing Ischemic Events and Causing Bleeding

Frontiers in Cardiovascular Medicine, 2022
Dual antiplatelet therapy comprising of aspirin and oral P2Y12 receptor antagonists are an established cornerstone of therapy in acute coronary syndromes and percutaneous coronary intervention.
Himawan Fernando, Himawan Fernando, Himawan Fernando, James D. McFadyen, James D. McFadyen, James D. McFadyen, James D. McFadyen, James D. McFadyen, Xiaowei Wang, Xiaowei Wang, Xiaowei Wang, James Shaw, James Shaw, Dion Stub, Dion Stub, Karlheinz Peter, Karlheinz Peter, Karlheinz Peter   +17 more
doaj   +1 more source

Role and recent progress of P2Y12 receptor in cancer development. [PDF]

Purinergic Signal
P2Y12 receptor (P2Y12R) is an adenosine-activated G protein-coupled receptor (GPCR) that plays a central role in platelet function, hemostasis, and thrombosis. P2Y12R activation can promote platelet aggregation and adhesion to cancer cells, promote tumor angiogenesis, and affect the tumor immune microenvironment (TIME) and tumor drug resistance, which ...
Xi Y, Min Z, Liu M, Lin X, Yuan ZH.
europepmc   +4 more sources

Cangrelor in STEMI as a bridge to CABG- a mini-case series

American Heart Journal Plus, 2022
Background: Patients with STEMI receive dual antiplatelet therapy as soon as possible with aspirin and a P2Y12 receptor antagonist prior to PCI. A fraction of these patients may have multi-vessel disease needing emergent CABG surgery.
Bishesh Shrestha, Daniel Katz, John Kelley, Dhananjai Menzies, Mun K. Hong   +4 more
doaj   +1 more source

P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: Meta-analysis

Journal of the Formosan Medical Association, 2022
Background/Purpose: Antiplatelet therapy is the cornerstone for acute ischemic stroke or transient ischemic attack (TIA). The purpose of this study was to conduct a meta-analysis to assess the efficacy and safety of P2Y12 receptor inhibitor plus aspirin ...
Wen-Yi Huang, Bruce Ovbiagele, Meng Lee
doaj   +1 more source

Association between P2Y12 inhibitor reloading and in-hospital outcomes for patients with non-ST-segment elevation acute coronary syndrome already on chronic P2Y12 receptor inhibitors therapy in China: findings from the CCC–ACS (improving care for cardiovascular disease in China-acute coronary syndrome) project

European Journal of Medical Research, 2023
Background The association between P2Y12 receptor inhibitors reloading and in-hospital outcomes in non-ST-segment elevation acute coronary syndrome (NSTEACS) patients who were on chronic P2Y12 receptor inhibitors therapy remained underdetermined. Methods
Yintang Wang, Yu Geng, Ou Zhang, Qin Xu, Yajun Xue, Boda Zhou, Ping Zhang, the CCC-ACS Investigators   +7 more
doaj   +1 more source

P2Y12 Receptors in Tumorigenesis and Metastasis [PDF]

Frontiers in Pharmacology, 2018
Platelets, beyond their role in hemostasis and thrombosis, may sustain tumorigenesis and metastasis. These effects may occur via direct interaction of platelets with cancer and stromal cells and by the release of several platelet products. Platelets and tumor cells release several bioactive molecules among which a great amount of adenosine triphosphate
Patrizia Ballerini, Patrizia Ballerini, Melania Dovizio, Melania Dovizio, Annalisa Bruno, Annalisa Bruno, Stefania Tacconelli, Stefania Tacconelli, Paola Patrignani, Paola Patrignani   +9 more
openaire   +3 more sources

Platelet P2Y12 Receptor Deletion or Pharmacological Inhibition does not Protect Mice from Sepsis or Septic Shock

TH Open, 2021
Introduction Platelets are increasingly appreciated as key effectors during sepsis, raising the question of the usefulness of antiplatelet drugs to treat patients with sepsis. Objective Evaluate the potential contribution of the platelet P2Y12
Yannick Rabouel, Stéphanie Magnenat, Xavier Delabranche, Christian Gachet, Beatrice Hechler   +4 more
doaj   +1 more source